Weak evidence for the management of medication-related osteonecrosis of the jaw: An overview of systematic reviews and meta-analyses.

Szczegóły
Abstrakt

Tytuł:: Weak evidence for the management of medication-related osteonecrosis of the jaw: An overview of systematic reviews and meta-analyses.
Autorzy:: Moraschini V; Dental Research Division, Department of Periodontology, School of Dentistry, Veiga de Almeida University, Rio de Janeiro, Brazil.
Calasans-Maia MD; Department of Oral Surgery, School of Dentistry, Fluminense Federal University, Niterói, Brazil.
Louro RS; Department of Oral Surgery, School of Dentistry, Fluminense Federal University, Niterói, Brazil.
Arantes EBR; Department of Oral Surgery, School of Dentistry, Fluminense Federal University, Niterói, Brazil.
Calasans-Maia JA; Department of Orthodontic, School of Dentistry, Fluminense Federal University, Niterói, Brazil.
Źródło:: Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology [J Oral Pathol Med] 2021 Jan; Vol. 50 (1), pp. 10-21. Date of Electronic Publication: 2020 Jul 12.
Typ publikacji:: Journal Article; Review
Język:: English
Imprint Name(s):: Publication: Oxford, UK : Wiley-Blackwell
Original Publication: Copenhagen : Munksgaard, c1989-
MeSH Terms:: Bisphosphonate-Associated Osteonecrosis of the Jaw*/therapy
Bone Density Conservation Agents*/adverse effects
Conservative Treatment ; Humans ; Meta-Analysis as Topic ; Systematic Reviews as Topic ; Treatment Outcome
References:: Marx RE, Sawatari Y, Fortin M, Broumand V. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg. 2005;63(11):1567-1575.
Hoefert S, Yuan A, Munz A, Grimm M, Elayouti A, Reinert S. Clinical course and therapeutic outcomes of operatively and non-operatively managed patients with denosumab-related osteonecrosis of the jaw (DRONJ). J Craniomaxillofac Surg. 2017;45(4):570-578.
Ruggiero SL, Dodson TB, Fantasia J, et al. American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw-2014 update. J Oral Maxillofac Surg. 2014;72(10):1938-1956.
Lopez-Jornet P, Sanchez Perez A, Amaral Mendes R, Tobias A. Medication-related osteonecrosis of the jaw: is autologous platelet concentrate application effective for prevention and treatment? A systematic review. J Craniomaxillofac Surg. 2016;44(8):1067-1072.
Khan AA, Morrison A, Hanley DA, et al. Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus. J Bone Miner Res. 2015;30(1):3-23.
El-Rabbany M, Sgro A, Lam DK, Shah PS, Azarpazhooh A. Effectiveness of treatments for medication-related osteonecrosis of the jaw: a systematic review and meta-analysis. J Am Dent Assoc. 2017;148(8):584-594.e582.
Beth-Tasdogan NH, Mayer B, Hussein H, Zolk O. Interventions for managing medication-related osteonecrosis of the jaw. Cochrane Database Syst Rev. 2017;10:CD012432.
Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol. 2009;62(10):1006-1012.
Schardt C, Adams MB, Owens T, Keitz S, Fontelo P. Utilization of the PICO framework to improve searching PubMed for clinical questions. BMC Med Inform Decis Mak. 2007;7:16.
Shea BJ, Reeves BC, Wells G, et al. AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. BMJ. 2017;358:j4008.
Dinu M, Pagliai G, Casini A, Sofi F. Mediterranean diet and multiple health outcomes: an umbrella review of meta-analyses of observational studies and randomised trials. Eur J Clin Nutr. 2018;72(1):30-43.
Bellou V, Belbasis L, Tzoulaki I, Evangelou E, Ioannidis JP. Environmental risk factors and Parkinson's disease: an umbrella review of meta-analyses. Parkinsonism Relat Disord. 2016;23:1-9.
Leewananthawet A, Arakawa S, Okano T, et al. Ozone ultrafine bubble water induces the cellular signaling involved in oxidative stress responses in human periodontal ligament fibroblasts. Sci Technol Adv Mater. 2019;20(1):589-598.
Pietrocola G, Ceci M, Preda F, Poggio C, Colombo M. Evaluation of the antibacterial activity of a new ozonized olive oil against oral and periodontal pathogens. J Clin Exp Dent. 2018;10(11):e1103-e1108.
Williams WB, O'Ryan F. Management of medication-related osteonecrosis of the jaw. Oral Maxillofac Surg Clin North Am. 2015;27(4):517-525.
Nicolatou-Galitis O, Schiodt M, Mendes RA, et al. Medication-related osteonecrosis of the jaw: definition and best practice for prevention, diagnosis, and treatment. Oral Surg Oral Med Oral Pathol Oral Radiol. 2019;127(2):117-135.
Kagami H, Inoue M, Kobayashi A, Taguchi A, Li X, Yoshizawa M. Issues with the surgical treatment of antiresorptive agent-related osteonecrosis of the jaws. Oral Dis. 2018;24(1-2):52-56.
Fortunato L, Bennardo F, Buffone C, Giudice A. Is the application of platelet concentrates effective in the prevention and treatment of medication-related osteonecrosis of the jaw? A systematic review. J Craniomaxillofac Surg. 2020;48(3):268-285.
Rupel K, Ottaviani G, Gobbo M, et al. A systematic review of therapeutical approaches in bisphosphonates-related osteonecrosis of the jaw (BRONJ). Oral Oncol. 2014;50(11):1049-1057.
Del Fabbro M, Gallesio G, Mozzati M. Autologous platelet concentrates for bisphosphonate-related osteonecrosis of the jaw treatment and prevention. A systematic review of the literature. Eur J Cancer. 2015;51(1):62-74.
Fliefel R, Troltzsch M, Kuhnisch J, Ehrenfeld M, Otto S. Treatment strategies and outcomes of bisphosphonate-related osteonecrosis of the jaw (BRONJ) with characterization of patients: a systematic review. Int J Oral Maxillofac Surg. 2015;44(5):568-585.
Rodriguez-Lozano FJ, Oñate-Sanchez RE. Treatment of osteonecrosis of the jaw related to bisphosphonates and other antiresorptive agents. Med Oral Patol Oral Cir Bucal. 2016;21(5):e595-e600.
Weber JB, Camilotti RS, Ponte ME. Efficacy of laser therapy in the management of bisphosphonate-related osteonecrosis of the jaw (BRONJ): a systematic review. Lasers Med Sci. 2016;31(6):1261-1272.
Rollason V, Laverriere A, MacDonald LC, Walsh T, Tramer MR, Vogt-Ferrier NB. Interventions for treating bisphosphonate-related osteonecrosis of the jaw (BRONJ). Cochrane Database Syst Rev. 2016;2:CD008455.
Comas-Calonge A, Figueiredo R, Gay-Escoda C. Surgical treatment vs. conservative treatment in intravenous bisphosphonate-related osteonecrosis of the jaws. Systematic review. J Clin Exp Dent. 2017;9(2):e302-e307.
Ramaglia L, Guida A, Iorio-Siciliano V, Cuozzo A, Blasi A, Sculean A. Stage-specific therapeutic strategies of medication-related osteonecrosis of the jaws: a systematic review and meta-analysis of the drug suspension protocol. Clin Oral Investig. 2018;22(2):597-615.
de Souza TE, de Castro TF, Michellon FC, et al. Adjuvant therapies in the management of medication-related osteonecrosis of the jaws: systematic review. Head Neck. 2019;41(12):4209-4228.
Heifetz-Li JJ, Abdelsamie S, Campbell CB, Roth S, Fielding AF, Mulligan JP. Systematic review of the use of pentoxifylline and tocopherol for the treatment of medication-related osteonecrosis of the jaw. Oral Surg Oral Med Oral Pathol Oral Radiol. 2019;128(5):491-497.e492.
Momesso GAC, Lemos CAA, Santiago-Junior JF, Faverani LP, Pellizzer EP. Laser surgery in management of medication-related osteonecrosis of the jaws: a meta-analysis. Oral Maxillofac Surg. 2020;24(2):133-144.
Jasper V, Laurence V, Maximiliaan S, Ferri J, Nicot R, Constantinus P. Medication-related osteonecrosis of the jaw (MRONJ) stage III: conservative and conservative surgical approaches versus an aggressive surgical intervention: a systematic review. J Craniomaxillofac Surg. 2020;48(4):435-443.
Moraschini V, de Almeida DCF, Figueredo CM, Calasans-Maia MD. Association between biomarkers and medication-related osteonecrosis of the jaws: a systematic review. Oral Surg Oral Med Oral Pathol Oral Radiol. 2019;127(6):504-515.
Favia G, Tempesta A, Limongelli L, Crincoli V, Maiorano E. Medication-related osteonecrosis of the jaw: surgical or non-surgical treatment? Oral Dis. 2018;24(1-2):238-242.
Bodem JP, Schaal C, Kargus S, et al. Surgical management of bisphosphonate-related osteonecrosis of the jaw stages II and III. Oral Surg Oral Med Oral Pathol Oral Radiol. 2016;121(4):367-372.
Atalay B, Yalcin S, Emes Y, et al. Bisphosphonate-related osteonecrosis: laser-assisted surgical treatment or conventional surgery? Lasers Med Sci. 2011;26(6):815-823.
Ersan N, van Ruijven LJ, Bronckers AL, Olgac V, Ilguy D, Everts V. Teriparatide and the treatment of bisphosphonate-related osteonecrosis of the jaw: a rat model. Dentomaxillofac Radiol. 2014;43(1):20130144.
Zandi M, Dehghan A, Zandipoor N, Amini P, Doulati S. Effect of different doses and durations of teriparatide therapy on resolution of medication-related osteonecrosis of the jaw: a randomized, controlled preclinical study in rats. J Craniomaxillofac Surg. 2018;46(3):466-472.
Owosho AA, Estilo CL, Huryn JM, Yom SK. Pentoxifylline and tocopherol in the management of cancer patients with medication-related osteonecrosis of the jaw: an observational retrospective study of initial case series. Oral Surg Oral Med Oral Pathol Oral Radiol. 2016;122(4):455-459.
Contributed Indexing:: Keywords: medication-related osteonecrosis of the jaw; osteonecrosis; treatment
Substance Nomenclature:: 0 (Bone Density Conservation Agents)
Entry Date(s):: Date Created: 20200627 Date Completed: 20210223 Latest Revision: 20220531
Update Code:: 20240105
DOI:: 10.1111/jop.13083
PMID:: 32589782
: Czasopismo naukowe

Full Text Finder

Background: Although several therapies are proposed for medication-related osteonecrosis of the jaw (MRONJ), to date there is no consensus or treatment protocol for MRONJ. This overview aims to summarize the available evidence on the management and outcomes of MRONJ.
Methods: An electronic search without language or date restrictions occurred in five databases and gray literature for articles published until March 2020. This overview was performed according to the PICO format. The eligibility criteria comprised systematic reviews (RS) with or without meta-analyses that analyzed treatments outcomes for MRONJ. The methodological quality of each SR was evaluated using AMSTAR 2.
Results: Fifteen studies published between 2014 and 2020 were included in this overview. The summary of the evidence showed that conservative treatment and low level laser therapy can yield favorable results for early stages of MRONJ whereas surgical treatment seems to be better for advanced stages. However, qualitative assessment of the SRs highlighted a global low level of quality.
Conclusions: There is weak evidence to support treatment protocols for MRONJ. Because of the low quality of the SRs, highlighted by this overview, no insightful therapeutic recommendations can be issued for any intervention for MRONJ.
(© 2020 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.)

Informacja